Back to Archived Journals » Orphan Drugs: Research and Reviews » Volume 5

Denosumab in the treatment of hypercalcemia secondary to malignancy

Authors Dalkin A, Rosner M

Received 21 August 2015

Accepted for publication 30 October 2015

Published 23 November 2015 Volume 2015:5 Pages 113—121


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Dr Lise Aagaard

Alan C Dalkin,1 Mitchell H Rosner2

1Division of Endocrinology and Metabolism, 2Division of Nephrology, University of Virginia Health System, Charlottesville, VA, USA

Abstract: Hypercalcemia secondary to malignancy is associated with serious morbidity and mortality. Current treatment paradigms focus on acute lowering of serum calcium with a combination of intravenous volume repletion and expansion coupled with therapies to decrease bone release of calcium (calcitonin, bisphosphonates). While highly effective, in some cases, patients may be refractory to these existing therapies or may not tolerate them. Recently, the role of receptor activator of nuclear factor-κB ligand in bone modeling has been elucidated and specific therapies to target this pathway have been developed. One of these therapies, denosumab has been effectively used in the management of postmenopausal osteoporosis. Given the important role of bone modeling in the development of malignancy associated hypercalcemia, denosumab has been used to treat this condition. This review focuses on the existing clinical data regarding denosumab for the treatment of hypercalcemia of malignancy.

Keywords: denosumab, hypercalcemia, malignancy, therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]